KOLKATA-BASED NEOMACHINE MFG CO was started in 1973 with an objective of manufacturing quality pharmaceutical machinery.

For a decade, the company catered to the requirements of the Indian pharma companies in injectable, liquid, tablet, capsule and ointment sections machinery.

While catering to this market segment, NEOMACHINE happened to come across a Kolkata-based pharmaceutical producer, who were envisaging problems in solvent-based film coating of tablets. Till then, the tablets were being coated in conventional pans, which were not only causing health hazards to the coating personnel, but was also a time consumingprocess.

During the last three decades, NEOMACHINE man- ufactured and marketed more than 600 machines, out of which 100 machines were exported to the different countries like the US, Australia, China, Jordan, Yemen, UAE, Uganda, Kenya, Sudan, Cyprus, Saudi Arabia, Austria, Brazil, Bangladesh and Bolivia, Nepal, Myanmar, Nigeria etc.

NEOMACHINE, a professionally managed organisation now has two manufacturing During the last three decades, NEOMACHINE manufactured and marketed more than 600 machines units in Kolkata, which are equipped with state-of-the-art equipment like fabrication, machining, assembling, finishing and other related jobs.
The company has been strictly following all the quality control guidelines during manufacturing. The boughtout items are inspected at the manufacturers’ works periodically.

The company has a dedicated team of engineers for providing erection and commissioning and prompt aftersales service to the clients.
The in-house R&D facility is abreast with latest technology upgradation and developments in ‘coating technology. This helps in continuous improvement of the product.

NEOMACHINE also provides DQ/IQ /OQ/ documents for automatic coating system and are in the process of getting CE certification. Neomachine being a single product company manufacturing only automatic coating system for coating of Pharma Tablets, Pellets & Gems Products has gained vast experiences in latest coating technology as well as validation and qualification of coating equipment to qualify for audit of various national and international agencies. The latest models of NEOCOTA are having all the constructional features for validation and qualification. The equipment are supplied with all the necessary documents for proper validation during installation and commissioning as well as trial production.

Inspired by this opportunity, NEOMACHINE started the process of developing an Automatic Coating Machine for tablets. After, two years of research and development, the first NEOCOTA Automatic Coating System was manufactured in 1984.

Over the years, the company has gained vast experiences in manufacturing ‘Automatic Coating System’ by interacting with various Indian & multinational pharma and confectionery units based in India and abroad.

The post NEOMACHINE MFG CO: A leader in automatic coating technology appeared first on Express Pharma.

THE UNITED ENGINEERING COMPANY (UEC) with the brand name ‘UNITED’ is known for being the pioneer and commander in packaging machinery manufacturing in India.

UEC, which was started in the year 1963 by GD Roy, has attained high reputation in providing machines and services of highest standards since the beginning. With the founder’s innovative ideas and unmatched leadership qualities, UEC crossed various boundaries in different fields of work.

Initiating the business with solutions for parenterals (ampoules and vials), UEC has diversified its business into the bottle packaging sector and has also mastered in providing machines for automatic tablet coating. UEC also provides customised solutions for its customers.

With a vision to provide the best pharmaceutical manufacturing technology, UEC has also ventured into different industries such as distilleries, cosmetics, foods and beverage, paints, chemicals, home care, office and student stationery and others.
The company has also expanded its footprints abroad in a large way. Today, ‘UNITED’ machines are exported to more than 21 countries across the globe namely the US, Canada, Bolivia, Nigeria, Kenya, the UAE, Iran, Sri Lanka, Bangladesh, Malaysia, Indonesia, Vietnam, Korea and others.

UEC puts in a lot of effort for their R&D and strives to provide the best and optimised solution to its customers. By virtue of dedication and continuous hard work of their R&D team, ‘UNITED’ machines provide technically advanced solution for its customers.

Presently UEC is having its head office in Kolkata. It has three manufacturing units in West Bengal, covering an area of over 10000 sq ft. UEC is having its marketing and sales office in Mumbai to cater to the eastern part of the nation and overseas. The company has also set up well equipped service shop in Mumbai to service its clients.

The United Engineering Company has been honoured by the prestigious ‘Innovator’s Award’ from the Indian Pharmaceutical Congress for their innovation and development and continuous value additions to the pharma packaging industry.
Today, at UEC, machines are equipped with the latest technology. For its customers, UNITED machines are cost effective but are guaranteed with the highest quality, optimum production and ensured unconditional service.

UEC is equally focused on being a corporate citizen. It has never shirked the responsibility of the society and has always been an active participant in numerous social events which help in uplifting the quality of living of the deprived.

With almost every pharma formulation manufacturer being an ‘UNITED’ machine user coupled with 50 years experience, UEC commits in becoming better than the best in the near future.

The post The United Engineering Company: Serving the pharma industry for the last five decades appeared first on Express Pharma.

THE UNITED ENGINEERING COMPANY (UEC) with the brand name ‘UNITED’ is known for being the pioneer and commander in packaging machinery manufacturing in India.

UEC, which was started in the year 1963 by GD Roy, has attained high reputation in providing machines and services of highest standards since the beginning. With the founder’s innovative ideas and unmatched leadership qualities, UEC crossed various boundaries in different fields of work.

Initiating the business with solutions for parenterals (ampoules and vials), UEC has diversified its business into the bottle packaging sector and has also mastered in providing machines for automatic tablet coating. UEC also provides customised solutions for its customers.

With a vision to provide the best pharmaceutical manufacturing technology, UEC has also ventured into different industries such as distilleries, cosmetics, foods and beverage, paints, chemicals, home care, office and student stationery and others.

The company has also expanded its footprints abroad in a large way. Today, ‘UNITED’ machines are exported to more than 21 countries across the globe namely the US, Canada, Bolivia, Nigeria, Kenya, the UAE, Iran, Sri Lanka, Bangladesh, Malaysia, Indonesia, Vietnam, Korea and others.

UEC puts in a lot of effort for their R&D and strives to provide the best and optimised solution to its customers. By virtue of dedication and continuous hard work of their R&D team, ‘UNITED’ machines provide technically advanced solution for its customers.

Presently UEC is having its head office in Kolkata. It has three manufacturing units in West Bengal, covering an area of over 10000 sq ft. UEC is having its marketing and sales office in Mumbai to cater to the eastern part of the nation and overseas. The company has also set up well equipped service shop in Mumbai to service its clients.

The United Engineering Company has been honoured by the prestigious ‘Innovator’s Award’ from the Indian Pharmaceutical Congress for their innovation and development and continuous value additions to the pharma packaging industry.

Today, at UEC, machines are equipped with the latest technology. For its customers, UNITED machines are cost effective but are guaranteed with the highest quality, optimum production and ensured unconditional service.

UEC is equally focused on being a corporate citizen. It has never shirked the responsibility of the society and has always been an active participant in numerous social events which help in uplifting the quality of living of the deprived.

With almost every pharma  formulation manufacturer being an ‘UNITED’ machine user coupled with 50 years experience, UEC commits in becoming better than the best in the near future.

The post The United Engineering Company: Serving the pharma industry for the last five decades appeared first on Express Pharma.

While catering to this market segment, NEOMACHINE happened to come across a Kolkata-based pharmaceutical producer, who were envisaging problems in film coating of tablets. Till then, the tablets were being coated in conventional pans, which were not only causing health hazards to the coating personnel, but was also a time – consuming process. Inspired by this opportunity, NEOMACHINE started the process of developing an automatic coating machine. After, two years of research and development, the first ‘Neocota Automatic Coating System’ was manufactured in 1984.

During the last three decades, NEOMACHINE manufactured and marketed more than 550 machines, out of which 100 machines were exported to the different countries like the US, Australia, China, Jordan, Yemen, the UAE, Uganda, Kenya, Sudan, Cyprus, Saudi Arabia, Austria, Brazil, Bangladesh and Bolivia etc.

NEOMACHINE, a professionally managed organisation now has two manufacturing units in Kolkata, which are equipped with state-of-the-art equipment like fabrication, machining, assembling, finishing and other related jobs.

The company has been strictly following all the quality control guidelines during manufacturing. The bought-out items are inspected at the manufacturers’ works periodically. The company has a dedicated team of engineers for providing erection and commissioning and prompt after-sales service to the clients.

The in-house R&D facility is abreast with latest technology upgradation and developments in ‘coating technology. This helps in continuous improvement of the product. NEOMACHINE also provides DQ/IQ/OQ/ documents for automatic coating system and are in the process of getting CE certification.

Over the years, the company has gained vast experiences in manufacturing ‘automatic coating system’ by interacting with various Indian and multinational pharma and confectionery units based in India and abroad.

Neomachine being a single product company manufacturing only automatic tablet coating system for coating of pharma tablets has gained vast experiences in latest coating technology as well as validation and qualification of coating equipment to qualify for audit of various national and international agencies. The latest models of NEOCOTA are having all the constructional features for validation and qualification. The equipment are supplied with all the necessary documents for proper validation during installation and commissioning as well as trial production.

The post NEOMACHINE MFG CO: A leader in automatic coating technology appeared first on Express Pharma.

Sanofi India signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, in the presence of Pranab Mukherjee, President, India. The collaboration with NIPER Kolkata, an autonomous body set up under the aegis of Department of Pharmaceuticals, GoI, will promote academic excellence and research in the areas of pharmaceuticals and consumer healthcare products, to cater to the current and future needs of the pharma industry.

Through this initiative, Sanofi India will

• Participate in revision or formulation of curriculum for a Post-Graduate (M.S.)/Ph.D. Programme
• Provide opportunities of internship or project work to NIPER Kolkata M.S./ Ph.D. students at manufacturing sites
• Ensure association of R&D heads with the dissertation work of NIPER Students
• Provide career growth opportunities
• Undertake collaborative research activities in identified areas

As per the MoU, the key deliverables for Sanofi India will be to assist NIPER Kolkata foster students with updated knowledge, and who are ready for the pharmaceutical industry.

• Repurposing of existing pharmaceuticals
• Novel small molecules for anti-diabetics and drug resistant tuberculosis
• API by Synthetic Biology/ Cell Factory
• Phyto-pharmaceuticals
• Rare diseases of public health importance

“The era of academia-industry collaboration to address the mammoth task of capacity building to meet our healthcare challenges has well and truly begun. Only a well-equipped and trained workforce can face future challenges and cater to the vast healthcare needs of the nation. We are proud to associate with NIPER Kolkata in this collaborative exercise to hone the students’ skill-sets, and empower them for future, based on our practical knowledge and research experience,” said Dr Shailesh Ayyangar, MD, Sanofi India.

EP News Bureau

The post Sanofi India collaborates with NIPER Kolkata appeared first on Express Pharma.

BCPL was formed by the great scientist Acharya PC Roy in 1901 and the company is running into losses for the past few decades. Explain why this company is in losses for a long time?

BCPL is a great company and it is the first pharma company in India established by great scientist Acharya P C Roy. Till early 1950s, it was running in profits but after the demise of Acharya PC Roy in 1944, from late 1950s, it started  running into losses. Due to its prolonged years of losses and labour unrest, BCPL was nationalised in 1981. Now, the company is owned  by Central Government. It was referred to the Board for Industrial and Financial Reconstruction (BIFR) in 1992 and was declared sick. But recently, the working culture has improved a lot. The reasons for losses were due to improper planning, labour unrest and also lack of team work.

What is the current status and future prospects of the company?

The company reported a net profit of Rs 1.16 crores in the first half, which ended on September 30, 2016 and is confident of reporting profits from 2016-17 onwards and it will be the turnaround year for the company. Further, during the last two years, the performance has improved a lot and in 2015-16 the company reported loss of Rs 9 crore against a loss of Rs.17 Crore in 2014-15 and a loss of Rs 37 crore in 2013-14. Recently, Bengal Chemicals was awarded “Excellent” rating in Corporate Governance from Department of Public Enterprises, Government of India for the financial year 2015-16.

What are the steps taken to turnaround this Company and to achieve Net Profit during 2016-17?

We have taken a number of steps to make it a profitable  in 2016-17 and we will take further steps to sustain the profitability in the long run. For example, we were able to negotiate for reduced interest rates on our loans from our bankers, able to procure raw and packing materials at lesser rates, able to reduce the administrative expenses, etc. and requested Government of India to reduce interest rates on government loans to match with the rates of commercial banks. Recently, we have developed financial discipline as well as operational discipline with which we will be able to sustain its profitability in the long run.

When did you join BCPL and what are the steps you have taken to change this company?

I have joined BCPL as Director (Finance) in November, 2014 and taken additional charge of MD from June, 2016. On the date of my joining, there were three annual accounts and six cost audits pending for finalisation and company was not able to finalise its accounts and submit the same to DPE/ Ministry because of which company’s MOU rating and Corporate Governance rating were rated poor for a number of years. After my joining, we have been able to conduct four AGMs and complete eight Cost Audit Reports within a short period of 16 months and BCPL has been the first Company, out of all the PSUs, to hold its Annual General Meeting of 2015-16 in July, 2016 itself. Due to the recent efforts, BCPL was able to get Excellent Corporate Governance Rating in 2015-16 from DPE. I had issued more than 60 Circulars/ Guidelines for improvement of systems. I have developed financial discipline through various ways such as:

• Opening more than 200 salary accounts of the employees (earlier salary was paid through cash)
• Closing of more than 30 inoperative/ less-operative bank accounts,
• Starting of rtgs/ neft payment
• Discontinuing cheque payments
• Installing cc tvs in the offices and factory premises,
• Monitoring advance payments to employees,
• Streamlining the suppliers payment system,
• Introduction of quarterly tendering system,
• Introduction of annual appraisal system for its employees

Further, as a part of improvement of the internal financial control systems in the company, we have stopped the entire cash transactions, opened separate bank account for collection of rental incomes, implementing five tier audit system  i.e. (i) Banking transaction audit (ii) Management cross audit of one unit’s accounts by other units’ officials (iii) Internal audit by the Chartered Accountants’ firm (iv) Statutory audit by the Audit firm appointed by CAG and (v) Government audit i.e. by CAG Auditors.

With the above steps taken, I am confident that we will become a profit making entity in 2016-17 itself and we have already reported net profit in the first half ended on September 30, 2016. We will sustain profitability in the long run with the help of guidelines/ circulars issued by me in the recent past, recent cost cutting measures taken as explained above and also due to the improvement in the Internal Financial Control Systems in the Company.

What are the major products on which the company will focus in future to improve its turnover and profitability?

The company has recently commissioned its plants to manufacture  various types of medicines. We will definitely focus more on the pharma division which is contributing more than 60 per cent of its turnover. Further,  Pheneol brand itself is able to take this company to greater heights. So, we will also concentrate more on home products like Pheneol, White Tiger, Naphthalene Balls, etc. for further growth. We have plans to achieve a turnover of Rs 200 crore by 2020 and also a matching respectable Net Profit on the said Turnover.

What is the message you want to give the loss making companies and also to their stakeholders?

The stakeholder of the loss making companies should vigilantly watch the activities and should analyse the reasons for their losses and take all necessary steps, without fear of losing popularity and favour to locality. They should also ensure that the company is in the right hands of a Chief Executive who will take up initiatives , treating the Company as his own , since he is one of the stakeholders and also a responsible citizen of the nation; then any sick company, whatever its activities may be and whichever the adverse conditions in which it is operating, will definitely become a Turnaround Company and sustain its activities and also keep its pride alive.

Message: “Keep your company in the hands of experienced, dynamic, honest and goal oriented leader for progress and sustainability”

EP News Bureau

The post BCPL: On the path of revival and growth appeared first on Express Pharma.

Kolkata’s leading pharma company, Albert David, a unit of Kothari Group, has initiated the process of opening a new division which would focus primarily in the therapeutic segments of gynaecology and orthopaedics and help the company achieve the growth objectives of the next five years.

To maintain its competitive edge in low price common dosage forms and to maintain the vibrancy of its product portfolio several newer formulations are being outsourced in line with the growth strategy of the company.  Reportedly, this move would also help the company to expand the customer base, product basket and its presence in various segments.

Currently, Albert David manufactures pharma formulations, bulk drugs and injections. It has manufacturing plants at Kolkata, Ghaziabad and Mandideep (Bhopal).  The Kolkata factory produces tablets, powders, small volume parenterals, oral liquids and bulk drugs.

The Ghaziabad plant manufactures IV fluids in glass and polyethylene containers using Blow Fill Seal Technology (BFS), small volume parenterals and capsules. Plant located at Mandideep is dedicated to produce disposable syringes and needles.

Technology upgradation and a fully revamped Research & Development (R&D) department would support the growth plans of the company with more in-line oral solids, liquids and sterile liquid dosage forms.

The company also has an active Export Division which is engaged in the process of developing specific dossiers for registration and future business in various countries.

The current export focus of Albert David Limited is restricted to the Rest of the World (ROW) markets.

In the last fiscal (2015-16), the company recorded a topline of Rs 321.30 crores and is expecting to touch Rs 345 crores by the end of March 2017.

The two launches, DHUP (Vitamin D3) and Inbalanse (Probiotic) would not only add to increase the net turnover of the company but will also open up newer therapeutic segment to ensure rapid growth and facilitate future launches.

Understanding the challenges which has risen due to various government policies, viz. FDC Ban, DPCO and stricter regulatory norms for both pharma formulations and FSSAI products, the company has put its strategies in place to tide over such hardships and sail through successfully to achieve its business goals.

EP News Bureau

The post Albert David to open new division to focus on gynaecology and orthopaedics appeared first on Express Pharma.

The alopathic system of medicine was introduced in India first time by the British ruler. Before the advent of British rule, the indigenous system of medicine, i.e ayurvedic, and unani, called Indian System of Medicine (ISM) were used in India. Mainly bulk drugs were manufactured by foreign companies in India and exported for converting into finished formulation to bring it back again to India. After the World War II, import of finished formulation were decreased significantly and indigenous companies tried to set up their own manufacturing facilities. The Calcutta Chemicals, Standard Chemicals and East India Chemicals were the pioneers to set up manufacturing facilities in West Bengal.

The Indian pharmaceutical industry can be said to have begun with the setting up of ‘Bengal Chemical and Pharmaceutical Works’ in Kolkata. Subsequently, institutes like Kings Institute of Preventive Medicine in Chennai, Pasteur Institute in Coonoor, the Central Drug Research Institute in Kasauli and others were set up. Post-independence, many other public sector companies such as Hindustan Antibiotics in 1954 and Indian Drugs and Pharmaceuticals in 1961 were set up to reduce the imports of important antibiotics and also to meet the county’s demand from indigenous production.

Today the pharma industry is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacturing and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.

The Indian pharma sector has 300 large units that control about 70 per cent of the market with market leader holding nearly seven per cent of the market share and about 8000 small scale units together which form the core of the pharma industry in India. These units produce the complete range of pharma formulations, i.e., medicines ready for consumption by patients and more than 400 bulk drugs, used for production of pharma formulations. Consequently, larger companies are cutting back on outsourcing and shifted to companies with facilities in the five tax-free states — Himachal Pradesh, Jammu & Kashmir, Uttaranchal, Sikkim and Jharkhand. SMEs have been finding it difficult to find the funds to upgrade their manufacturing plants, resulting in the closure of many facilities.

In 2005, India introduced product patent recognition to all new chemical entities (NCEs) i.e., bulk drugs developed then onwards. This introduction of product patent regime from January 2005 is leading into long-term growth for the future which mandated patent protection on both products and processes for a period of 20 years. Under this new law, India will be forced to recognise not only new patents but also any patents filed after January 1, 1995. The Indian pharma industry is mounting up the value chain. From being a pure reverse engineering industry focused on the domestic market, the industry is moving towards basic research driven, export-oriented global presence, providing a wide range of value added quality products and services, innovation, product life cycle management and enlarging their market reach. The old and mature categories like anti-infectives, vitamins, analgesics are de-growing while, new lifestyle categories like cardiovascular, Central Nervous System (CNS), anti diabetic and anti-cancer drugs are expanding at double-digit growth rates.

Domestic market

The industry has enormous growth potential. The factors are listed below:

• The large population of over of a billion
• Increasing income capacity
• Demand for quality healthcare
• Change in disease patterns
• Increased demand for new medicines to combat lifestyle related diseases

More than 85 per cent of the formulations produced in the country are sold in the domestic market. India is largely self-sufficient in case of formulations. Some life saving, new generation under-patent formulations continue to be imported, especially by MNCs, which then market them in India. Overall, the size of the domestic formulations market is around Rs 160 billion and it is growing at 10 per cent per annum.

Export potential

The pharma sector is one of India’s most important sectors in terms of projected revenue growth from exports and for meeting the needs of Indian population. There are a larger number of markets to which Indian pharma companies can now export as a result of global trade liberalisation and capacity building by Indian companies over the last decade.

Pharma sector in Bengal

Agriculture is the backbone of the West Bengal’s economy. Industrial and services sector also contribute to the development of the state economy. Pharma industries, especially formulation units, require less land compared to other heavy Industries; Return on Investment (RoI) is fast and very good. In modern pharma industry one requires less but highly qualified and skilled manpower, which is available in the state as it is evident from the fact that many personnel from the state of West Bengal are holding high position in the pharma industry in other parts of the country.

Advantages of pharma industry in West Bengal

• Potential market with a target large population in the eastern and north eastern states.
• Successful implementation of land reforms, the rural economy has developed resulting increase of purchasing power.
• Prime medical facility in Kolkata, Durgapur and Siliguri for patient from neighbouring countries, especially Bangladesh, Nepal and Bhutan
• NIPER campus has established in the state.
• A proposed pharma manufacturing zone and chemical hub
• Special Export Processing Zone (SEPZ) at Falta
• NPPA-CIFG in Kolkata for redresse the grievances of consumer
• Biotech Policy is declared
• Country’s main Patent office in Kolkata.

The State Government is adopting a number of policy measures to accelerate the industry’s growth and to make it internationally competitive.

Thrust areas of policy

• Industrial licensing for all bulk drugs cleared by Drug Controller General (India), all their intermediaries and formulations will be abolished, subject to stipulations laid down from time to time.
• Create an incentive framework for the pharma industry, which promotes new investments and encourages the introduction of new technologies as well as new drugs.
• Permit Foreign Investment up to 100 per cent excepting in a few areas. The Government is also making arrangements for the automatic approval for Foreign Technology Agreements for all bulk drugs cleared by Drug Controller General (India), all their intermediaries and formulations excepting some designated items.

The Directorate of Drugs Control of the State has extended a helping hand to the pharma producers in meeting global standards in stages. Since all surviving industries in West Bengal are GMP compliant, requirements of advanced tools and technology, validated and aseptic processing will no more be a problem. The West Bengal Government is planning to announce a comprehensive drug policy for the state. A strong motivation within the pharma industry is now required to regain its lost pride and position. The effect was negated in government taxation and pricing policies.

The post Pharma industries in West Bengal appeared first on Express Pharma.

Kolkata-based pharmaceutical company Albert David, a unit of the Kothari group, has recently undertaken a range of initiatives for the development of new products for increasing its market share in formulation segment to achieve sustained growth in the current fiscal year.

“In the current fiscal, we have introduced new products and would be soon adding more brands to expand our product basket,” said Kamal Prasad Mundhra, Executive Director, Albert David.

Albert David, which makes pharma formulations, bulk drugs and injections, has three manufacturing plants — in Kolkata (for tablets and powder, small volume parenterals, oral liquids, bulk drugs), Ghaziabad (for IV fluids in glass and polythene containers using the latest Form-Fill-Seal (FFS) technology and small volume parenterals) and Mandideep (disposable syringes and needles).

In the last fiscal (2013-14), the company, touched a turnover of Rs 292 crores and is expecting to touch Rs 330 crores by March 2015.

The company has successfully launched Rabeprazole and its combination (Anti-peptic ulcerant range) and Montelukast and its combination (anti-asthmatic range).

New formulations have been launched in the therapeutic segments like anti-asthmatics (for the treatment of seasonal allergic rhinitis), anti-ulcerants another proton pump inhibitor and nutritional supplements in the treatment of patients with malnutrition, stress and convalescence, debility, etc.

During the current financial year, the company plans to further strengthen Alamin range of products by launching alamin liquid, alamin drops and other variants of L Arginine sachets.

He said, “We also have plans to venture into pre-probiotic, infertility and nutraceuticals market.”

Mundhra said, “The company has given much thrust on its research and development initiatives. The company has made significant investments in fully renovating and expanding its R&D facility at Kolkata. The facility had been further equipped with more analytical and functional instruments as well as manpower to enhance its R&D capability to deliver more advanced and efficacious dosage forms in oral solids, oral liquid and some APIs. A number of R&D projects in product and process development have been taken up, which is at different stages of development.”

To expand the geographical reach of the company’s products in export market, a number of dossiers have been submitted in different countries. Approval of some dossiers has been received during this financial year.

Commenting on the Indian pharma industry, he said it is an extremely fragmented market with severe price competition and government price control.

But inspite of these, Albert David will continue to grow with the current strategies in place and is equipped to meet any future challenges, he added.

EP New Bureau – Kolkata

The post Albert David to tap new markets appeared first on Express Pharma.

Kolkata-based pharmaceutical company STADMED has achieved remarkable growth in the last three years. Stadmed is focusing more on the domestic market to catch up with the growth driven by the small and mid sized Indian pharma companies.

In recent past, the company has launched 20 new brands including brand’s extensions, out of which 12 brands are successfully growing and competing strongly with the leaders to enhance the market share. It has created more rural headquarters to increase its reach to various types of medical practitioners.

The company is aiming to increase its prescriber base and area of operation in domestic retail pharma market. Stadmed is growing rapidly in Andhra Pradesh and Telengana and has objectives to operate in these states in full capacity by the year end.

Research and development and formulations are the other areas the company has focused upon. Stadmed successfully developed innovative release method in specific drug category viz. pain, nutrition supplement, sedative hypnotics etc. The company is dedicated to provide quality medicines since seven decades. Growing demand and growth in business has been a challenge for the company to meet.

With a field force of 400, the company is able to retain its talents. Formation of different strategic business unit (SBU) and segment-wise promotion is the motto of the company. At present, the company has two SBUs and has plans to increase it by four in the next couple of years. The represented product market is immensely potential and addition of brands in urology, paediatrics and in chronic care segments have strengthened the product portfolio.

Asheesh Roy, Director Sales and Marketing, Stadmed says, ‘We are optimistic to reach newer heights within the next few years. The rich experience and market image of the company will drive us faster to achieve the Rs 200-crore. mark sooner. The unique drug delivery system in recently launched ‘Urifur-SR’ (Nitrofurantoin sustained release tablet) has given us success for better patient compliance at most affordable price. We are aiming to create more SBUs for more focused promotion.’”

EP News Bureau – Kolkata

The post STADMED to focus more on the domestic market appeared first on Express Pharma.